SCHEMBL7104048

SCHEMBL7104048

CCCCCNC(=O)C(NC(=O)C(Br)Cc1ccccc1)C(=O)NCCCCC

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 3/20 0.51
HPGD P15428 2/20 0.49
CHRNB2 P17787 1/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
CHRNA4 P43681 1/20 0.47
TLR2 O60603 1/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
REN P00797 1/20 0.46
CNR2 P34972 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
PTPN1 P18031 1/20 0.44
EPHX1 P07099 3/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7104044 1.00 NAAA (0.51) NAAAHPGDCHRNB2CHRNB4CHRNA3
SCHEMBL7098758 0.87 MMP8 (0.58) KMT2ACNR2CYP2D6CYP2C9CYP2C19
SCHEMBL7098762 0.87 MMP8 (0.58) KMT2ACNR2CYP2D6CYP2C9CYP2C19
SCHEMBL7098130 0.85 MME (0.53) NAAAHPGDCHRNB2CHRNB4CHRNA3
SCHEMBL7098126 0.85 MME (0.53) NAAAHPGDCHRNB2CHRNB4CHRNA3
SCHEMBL7104103 0.84 NAAA (0.48) NAAAHPGDCHRNB2CHRNB4CHRNA3
SCHEMBL7104110 0.84 NAAA (0.48) NAAAHPGDCHRNB2CHRNB4CHRNA3
SCHEMBL7101423 0.84 KMT2A (0.51) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL7101421 0.84 KMT2A (0.51) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL7102726 0.81 MMP8 (0.54) KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140818-B1 AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE AVENTIS PHARMA INC (US) 2003-09-10 EP disclosed
US-6329550-B1 FOR THERAPY OF EMPHYSEMA, OSTEOPOROSIS, RHEUMATOID ARTHRITIS AND NEOPLASTIC DISEASES AVENTIS PHARMACEUTICALS INC. 2001-12-11 US disclosed